-
acquired Viewics, Inc. In late
December the
company announced it
would acquire Ignyta Inc,
expanding its
global oncology business. In
February 2018,
Roche announced...
-
Investigations of
entrectinib were
conducted by
Ignyta Pharmaceuticals. On 21
December 2017,
Roche announced plans to buy
Ignyta for $1.7 billion.
Entrectinib is the...
-
anesthetic procedures. In
March 2015, Teva sold four anti-cancer
compounds to
Ignyta Inc. for $41.6 million. As part of the deal Teva sold the
following compounds...
-
Entrectinib (formerly RXDX-101,
trade name Rozlytrek) is a drug
developed by
Ignyta, Inc.,
which has
antitumor activity. It is a
selective pan-trk receptor...
-
multiple targets BMS
Small molecule 2006
Entrectinib TrkA/TrkB/TrkC/ROS1/ALK
Ignyta Small molecule 2004
Erdafitinib FGFR
Janssen Small molecule 2019 Erlotinib...
-
Entrectinib (formerly RXDX-101) is an
investigational drug
developed by
Ignyta, Inc.,
which has
potential antitumor activity. It is a
selective pan-trk...
- ****ociate Vice
Chancellor for
Health Sciences. He is the co-founder of
Ignyta, Inc., a
biotech company that went
public in 2015 and was
acquired by Roche...
-
Entrectinib (RXDX-101) is a
selective tyrosine kinase inhibitor developed by
Ignyta, Inc., with specificity, at low
nanomolar concentrations, for all of three...
-
being investigated for RET inhibition, RXDX-105 was
being developed by
Ignyta as a VEGF-sparing
multikinase inhibitor of BRAF, RET and EGFR. It was discontinued...
- to one
prior chemotherapy)
Entrectinib (Nerviano's NMS-E628,
licensed by
Ignyta and
renamed RXDX-101, in the U.S.
orphan drug
designation and rare pediatric...
